<DOC>
	<DOCNO>NCT00903799</DOCNO>
	<brief_summary>The aim clinical trial ass symptomatic efficacy impact utilization healthcare resource treatment gastric electrical stimulation ( ENTERRA ® ) patient refractory nausea and/or vomit leading nutritional impairment . Eligible patient refractory symptom either idiopathic , postsurgical due diabetes mellitus . The duration study 28 month patient . After run-in period 4 month prospective assessment healthcare resource utilization severity symptom obtain , patient implant . The follow-up period implantation device last 24 month every patient divide two part : ) After first postoperative month device remain `` OFF '' position , first phase study randomize double-blind cross-over study 2 period 4 month device activate . After 9th month follow , trial open trial device activate patient . During whole trial , patient record type healthcare resource utilization ( hospitalization , drug treatment , endoscopic procedures… ) symptomatic efficacy treatment assessed standard questionnaire follow visit schedule 1 , 5 , 9 , 12 , 18 , 24 month . The glycemic control determine visit diabetic patient . A delayed gastric empty selection criterion plan analyze clinical result treatment take account delay normal gastric empty pre-implantation period . Moreover , gastric empty study schedule 5 , 9 , 12 24 month test impact gastric electrical stimulation gastric emptying .</brief_summary>
	<brief_title>Medico-economic Evaluation ENTERRA Therapy</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Nausea and/or vomit refractory prokinetics antiemetic fulfil follow criterion 1 . Due diabetes mellitus type 1 , secondary oesogastric surgery ( vagotomy , partial gastric resection ) idiopathic 2 . Non related cause 3 . Chronic ( duration &gt; 12 month ) 4 . Occurring least weekly 5 . Refractory antiemetic ( chlorpromazine , ondansétron , granisétron ) and/or prokinetics ( domperidone , metoclopramide , erythromycin ) , 6 . Leading weight loss significant reduction food intake 7. occur patient without contraindication surgical implantation device , particular severe cardiac respiratory failure haemostasis disorder , 8. patient old 18 year 9. negative pregnancy test entry trial woman 10 . Patients sign study consentment 11 . Affiliation welfare system 1 . Patients old 70 , 2 . Patients nausea and/or vomit relate another aetiology previously describe . 3 . Patients absolute contraindication general anaethesia surgery 4 . Patients contraindication implantation device 5 . Patients severe psychiatric disorder 6 . Patients guardianship curatorship 7 . Patients major obesity severe eat disorder . 8 . Patients unable understand French . 9 . Pregnant woman nurse mother 10 . Lack effective contraception 11 . Patients undergone pancreatic graft within previous 6 month unstable clinical condition enrollment 12 . Patients underlying disease lead followup MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Drug-refractory gastroparesis</keyword>
	<keyword>diabetes mellitus induced gastroparesis</keyword>
	<keyword>Gastric electrical stimulation</keyword>
	<keyword>Long-term multicenter study</keyword>
</DOC>